Abstract
Objectives The SARS-CoV-2 JN.1 lineage emerged in late 2023 and quickly replaced the XBB lineages, becoming the predominant Omicron variant worldwide in 2024. We estimate the epidemiological impact of this SARS-CoV-2 lineage replacement in Brazil and we further assessed the cross-reactive neutralizing antibody (NAb) responses in a cohort of convalescent Brazilian patients infected during 2023.
Methods We analyzed the evolution of SARS-CoV-2 lineages and severe acute respiratory infection (SARI) cases in Brazil between July 2023 and March 2024. We evaluated the cross-reactive NAb responses to the JN.1 variant in a cohort of convalescent Brazilian patients, both before and after infection with XBB.1* lineages.
Results JN.1 replaced XBB with similar temporal dynamics across all country regions, though its epidemiological impact varied between locations. The Southeastern, Southern, and Central-Western regions experienced a brief XBB wave around October 2023, shortly before the introduction of JN.1, without any immediate upsurge of SARI cases during viral lineage replacement. By contrast, the Northeastern and Northern regions did not experience an XBB wave in the latter half of 2023 and displayed a rapid surge in SARI cases driven by the emergence of the JN.1. We found that recent XBB infections in the Brazilian population significantly boosted cross-reactive NAb levels against JN.1.
Conclusions The XBB wave observed in the second half of 2023 in some Brazilian states likely acted as a booster for population immunity, providing short-term protection against JN.1 infections and delaying the rise of SARI cases in certain regions of the country.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding support from Carlos Chagas Filho Foundation for Research Support in the State of Rio de Janeiro (FAPERJ) (FAPERJ E-26/211.125/2021), National Council for Scientific and Technological Development (CNPq), Ministry of Science, Technology and Innovations (MCTI) and the Latin American Biotechnology Center (CABBIO) (CNPq/MCTI 17/2021, 423857/2021-5). P.C.R. had support from CNPq (Productivity fellowship 311759/2022-0). I.A. had support from FAPERJ (grant SEI-260003/019669/2022). G.L.W. had support from CNPq (Productivity fellowship 307209/2023-7). P.B. had support from FAPERJ (E-26/200.935/2022) and CNPq (311562/2021-3).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Brazilian National Committee of Ethics in Research (CONEP) gave ethical approval for this work (protocol number: 30639420.0.0000.5262).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵‡ These authors share the senior authorship.
